Jazz Launches $1B Exchangeable Notes Offering With $225M Buyback
JAZZ has more than doubled off its 52-week low of $122.5 on elevated volume (1.9× avg).
Summary
Jazz Pharmaceuticals is raising $1.1 billion through a private offering of exchangeable senior notes due 2032, upsized from the initially announced $1.0 billion, with a 13-day option for initial purchasers to buy up to $150 million more. The notes carry a 1.875% coupon and are expected to close on August 31. Concurrently, the company plans to repurchase up to $225 million of its ordinary shares. Net proceeds are earmarked for general corporate purposes. The offering is notable given Jazz's recent M&A activity, including the $820 million Actio Biosciences acquisition announced earlier this month, and follows strong Q2 results and the FDA approval of Ziihera for first-line HER2+ gastroesophageal cancer. The exchangeable structure and concurrent buyback suggest a balanced approach to capital management, though the dilution impact will depend on conversion terms not yet disclosed.
Updated with a Dow Jones Newswires report · What changed
Updates
· Dow Jones Newswires — Jazz expects net proceeds of $1.08 billion from the upsized offering, rising to $1.23 billion if the underwriters' option is exercised in full. The company also agreed to a concurrent $225.0 million share repurchase from note purchasers.
· Dow Jones Newswires — The offering was upsized to $1.1 billion from the initially announced $1.0 billion, with a 13-day option for an additional $150 million. The notes carry a 1.875% coupon and are expected to close on August 31.
At the time of this announcement, JAZZ was trading at $254.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $16.9B. The 52-week trading range was $122.50 to $266.38. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: Reuters.